SLU-PP-332
Low EvidenceA synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health.
What It Is
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) — orphan nuclear receptors that act as master regulators of mitochondrial biogenesis, oxidative metabolism, and the endurance adaptations normally triggered by physical exercise. It was first reported by Thomas Burris and colleagues, and the 'SLU' in its name reflects its Saint Louis University origin. Although it is widely sold and discussed in the peptide research community, SLU-PP-332 is not a peptide — it is a synthetic small molecule, grouped with compounds like 5-Amino-1MQ as a metabolic 'research compound.' Because ERRα drives the transcriptional program that builds slow-twitch oxidative muscle fibers and increases fatty-acid oxidation, activating these receptors pharmacologically is hypothesized to reproduce some downstream effects of training without the training itself — hence the 'exercise mimetic' label that has driven its popularity. In preclinical work, SLU-PP-332 increased oxidative (Type IIa) muscle fibers, fatty-acid oxidation, and treadmill endurance in mice in an ERRα-dependent manner; in mouse models of metabolic syndrome it raised energy expenditure, improved insulin sensitivity, reduced fat mass without reducing food intake, and showed cardiac protection against pressure-overload heart failure. As of June 2026, there are no published human clinical trials of SLU-PP-332. It is not FDA-approved, is sold strictly as a research-use-only chemical, and — notably — anti-doping laboratories have begun publishing detection methods for it, a signal that it is already being used off-label by athletes despite the absence of human safety data.
Why Researchers Study It
SLU-PP-332 targets a fundamentally different node than incretin (GLP-1) therapies: instead of suppressing appetite, it activates the ERR transcriptional program that governs mitochondrial density and oxidative metabolism in muscle. Researchers are interested in whether 'exercise in a pill' can improve endurance, fat oxidation, and insulin sensitivity — and whether ERR agonism could preserve muscle quality alongside GLP-1-driven weight loss, where lean-mass loss is a recognized concern. It is also a test case for how the metabolic research-compound market behaves ahead of any regulatory framework.
Proposed Mechanisms
- Pan-agonist of estrogen-related receptors ERRα, ERRβ, and ERRγ (highest potency at ERRα)
- Drives mitochondrial biogenesis and oxidative phosphorylation gene programs
- Increases fast oxidative (Type IIa) skeletal muscle fibers and fatty-acid oxidation
- Raises whole-body energy expenditure without reducing food intake (preclinical)
- Improves insulin sensitivity in diet-induced obese mice in an ERRα-dependent manner
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Preclinical (mouse) | Diet-induced obese and metabolic-syndrome mice | Increased energy expenditure and insulin sensitivity; reduced fat mass without reduced food intake | Source |
| Preclinical (mouse) | Skeletal muscle / exercise endurance | Increased Type IIa oxidative fibers, fatty-acid oxidation, and treadmill endurance in an ERRα-dependent manner | Source |
| Analytical / doping control | In vitro human metabolite profiling | Detection assay and metabolite markers established for anti-doping screening — evidence of real-world athletic use | Source |
Commonly Discussed Benefits
Researching SLU-PP-332? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- No published human clinical trials — all efficacy data are preclinical (cell and mouse)
- Not a peptide — it is a synthetic small-molecule ERR agonist
- Not FDA-approved and not on the FDA's July 2026 PCAC compounding review list
- Sold strictly as a research-use-only chemical; gray-market product purity and identity are frequently unverified
- Long-term safety, carcinogenicity, and cardiovascular risk in humans are unknown
- Prohibited-list / doping-control interest: anti-doping labs have published detection assays, indicating athletic misuse
Comparisons
See how SLU-PP-332 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Billon C. et al. — A synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome. J Pharmacol Exp Ther / ScienceDirect 2024 PubMed
- [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — PMC 2026 PubMed
- [3] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — PubMed 2026 PubMed
Keep researching in the app
- Log SLU-PP-332 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
AOD-9604
Medium EvidenceA modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects.
5-Amino-1MQ
Low EvidenceA small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.